Business

India’s Pharma Market Grows 8.4% In FY25; Boosted By Chronic Therapies & New Drug Launches

India’s pharma market grew by 8.4% during the financial year 2024-25, propelled by strong performance in key chronic therapy areas, according to market research firm Pharmarack.

The cardiac segment led with a 10.8% value growth, followed closely by gastrointestinal (10.2%) and anti-diabetic (8%) therapies.

Together, these three therapy areas contributed 34% of the total pharma market sales, helping push the industry’s overall turnover to over ₹2.25 trillion.

Top-Selling Drugs Led By Chronic Treatments

Despite the chronic therapies dominating in growth, GSK’s antibiotic Augmentin emerged as the top-selling drug of FY25 with ₹816 crore in sales.

USV’s Glycomet GP, an anti-diabetic medication, followed closely with ₹803 crore in sales.

While value growth was strong, unit sales in the domestic market recorded a modest 1.2% increase, indicating that growth was largely price-driven.

Empagliflozin Patent Expiry Sparks Price War

March 2025 saw a significant market shift with the diabetes molecule empagliflozin going off-patent.

Within a month, 86 brands from 19 companies launched empagliflozin-based products. Sheetal Sapale, vice-president (commercial) at Pharmarack, noted a steep price drop—around 85%—with prices falling from ₹60-70 per tablet to just ₹5-15.

Despite a rise in volume, the value declined due to this price erosion.

Anti-Obesity Market Gets Boost From Mounjaro

The launch of Eli Lilly’s Mounjaro (tirzepatide) in March 2025 added momentum to India’s emerging anti-obesity market.

In just one month, Mounjaro contributed ₹1.4 crore to the segment’s ₹576 crore moving annual turnover. Semaglutide, another GLP-1-based drug, accounted for 69% of this total over the previous 12 months.

Double-Digit Growth For Leading Companies

Several leading pharma companies posted strong domestic value growth in March 2025. Sun Pharma (14.9%), Torrent Pharma (14.7%), Intas (12.8%), and Zydus (10.8%) all recorded double-digit growth.

Overall, the pharma market witnessed a 7.5% value growth and 1.8% unit growth in March alone, reflecting broad-based strength across segments.

Also Read: India’s $2.7 Billion PLI Scheme Set To Boost Local Electronics Manufacturing

Purnima Mishra

Recent Posts

Neurosurgeon Reveals Everyday Habits That Gradually Harm Brain Health

Neurosurgeon Dr Richard Veyna warns that poor sleep, stress, inactivity, and sugary diets can harm…

2 hours ago

Amazon Diwali Sale: Last-Minute Smartphone Deals You Can Grab Before October 20

Amazon Diwali sale ends October 20; grab last-minute deals on Samsung, Apple, OnePlus, Realme, and…

2 hours ago

Government Extends GSTR-3B Filing Deadline By Five Days Owing To Festive Season

The government has extended the GSTR-3B filing deadline to 25 October 2025, giving taxpayers extra…

3 hours ago

Virat Kohli Returns To International Cricket; Claims Peak Fitness After Hiatus

Virat Kohli returns to international cricket for India’s ODI series in Australia, asserting peak fitness…

5 hours ago

Ibrahim Ali Khan Shares Festive Selfie With Brothers Taimur And Jeh; Calls Them ‘Teeno Bhai Teeno Tabahi’

Ibrahim Ali Khan celebrates Diwali with a festive selfie alongside his younger brothers Taimur and…

6 hours ago

US Destroys Drug-Smuggling Submarine In Caribbean; Repatriates Survivors To Colombia And Ecuador

President Donald Trump confirms the destruction of a drug-carrying submarine in the Caribbean, with two…

6 hours ago